Considerations Left behind Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Outbreaks in Republic of Korea.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Current advances in the development of SARS-CoV-2 vaccines.International journal of biological sciences · 2021
   Review
2. Stochastic model of the transmission dynamics of COVID-19 pandemic.Advances in difference equations · 2021
   Article
3. Diagnostic delays in 537 symptomatic cases of Middle East respiratory syndrome coronavirus infection in Saudi Arabia.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2017
   Article
4. A Comparison of the Cambodian and the South Korean Health Care System.Journal of menopausal medicine · 2016
   Article
5. Camel exposure and knowledge about MERS-CoV among Australian Hajj pilgrims in 2014.Virologica Sinica · 2016
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.